These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26733555)

  • 1. Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.
    Eaton AA; Sima CS; Panageas KS
    J Natl Compr Canc Netw; 2016 Jan; 14(1):57-65. PubMed ID: 26733555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.
    Etan T; Amir E; Tibau A; Yerushalmi R; Moore A; Shepshelovich D; Goldvaser H
    Cancer Treat Rev; 2020 Dec; 91():102113. PubMed ID: 33128993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
    Conti RM; Bernstein AC; Villaflor VM; Schilsky RL; Rosenthal MB; Bach PB
    J Clin Oncol; 2013 Mar; 31(9):1134-9. PubMed ID: 23423747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
    Kehl KL; Niu J; Chavez-MacGregor M; Giordano SH
    Cancer; 2018 Dec; 124(24):4685-4691. PubMed ID: 30264853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
    Kurzrock R; Gurski LA; Carlson RW; Ettinger DS; Horwitz SM; Kumar SK; Million L; von Mehren M; Benson AB
    Ann Oncol; 2019 Oct; 30(10):1647-1652. PubMed ID: 31373348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
    Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
    [No Abstract]   [Full Text] [Related]  

  • 10. Potentially inappropriate medication use in older patients with breast and colorectal cancer.
    Karuturi MS; Holmes HM; Lei X; Johnson M; Barcenas CH; Cantor SB; Gallick GE; Bast RC; Giordano SH
    Cancer; 2018 Jul; 124(14):3000-3007. PubMed ID: 29689595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
    Barcenas CH; Niu J; Zhang N; Zhang Y; Buchholz TA; Elting LS; Hortobagyi GN; Smith BD; Giordano SH
    J Clin Oncol; 2014 Jul; 32(19):2010-7. PubMed ID: 24868022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of the SEER-Medicare data to identify chemotherapy use.
    Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
    Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Comparison of Newly Diagnosed Invasive Breast Patient Cohorts in Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC) and Other Real-World Databases.
    Liu X; Alipour GH; Shao C; Burcu M; Bortnichak E; Vo T; Yu CL
    Pharmacoepidemiol Drug Saf; 2024 Aug; 33(8):e5851. PubMed ID: 39090803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the association between adjuvant chemotherapy and function-related adverse events among older patients with early stage breast cancer.
    Mariano C; Lund JL; Peacock Hinton S; Htoo P; Muss H; Reeder-Hayes KE
    J Geriatr Oncol; 2017 Jul; 8(4):242-248. PubMed ID: 28601373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer.
    Karuturi MS; Holmes HM; Lei X; Johnson M; Barcenas CH; Cantor SB; Gallick GE; Bast RC; Giordano SH
    J Geriatr Oncol; 2019 Sep; 10(5):705-708. PubMed ID: 30795923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-related cardiotoxicity among older patients with breast cancer.
    Chavez-MacGregor M; Zhang N; Buchholz TA; Zhang Y; Niu J; Elting L; Smith BD; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2013 Nov; 31(33):4222-8. PubMed ID: 24127446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
    Gold HT; Do HT
    Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
    Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
    Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
    Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL
    Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.